A phase I clinical trial assessing IN-119873
Latest Information Update: 01 Apr 2024
At a glance
- Drugs IN 119873 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 01 Apr 2024 New trial record
- 27 Mar 2024 According to HK inno.N media release, the goal of the company is to complete non-clinical research and apply for a phase 1 clinical trial (IND) within the year.